The current state of multidrug-resistant gram-negative bacilli in North America: Insights from the society of infectious diseases pharmacists

Pharmacotherapy

Volumn 28, Issue 2, 2008, Pages 235-249

  Nicasio, Anthony M ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Gram negative bacilli; Multidrug resistance; Treatment options

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CEPHALOSPORINASE; CEPHAMYCIN DERIVATIVE; COLISTIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; METALLO BETA LACTAMASE; MINOCYCLINE; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PENICILLINASE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; POLYMYXIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; TIGECYCLINE; UNINDEXED DRUG;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NORTH AMERICA; PHARMACIST; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; SHORT SURVEY; UNITED STATES;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MINOCYCLINE; NORTH AMERICA; POLYMYXINS; SULBACTAM;

EID: 38849186031     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.2.235     Document Type: Short Survey

References (142)

1. Dineen P. Staphylopenicillinase: its role in penicillin resistance - an alternate method of penicillin resistance in vivo by Staphylococcus aureus. J Surg Res 1964;4:183-91.
2. Mitchell AA. New epidemic strain of Staphylococcus aureus: emergence and spread in a general hospital. Lancet 1964;37:859-62.
3. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005;41: 848-54.
4. Albrecht SJ, Fishman NO, Kitchen J, et al. Reemergence of gram-negative health care-associated bloodstream infections. Arch Intern Med 2006;166:1289-94.
5. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature 1940;41:848-54.
6. Infectious Diseases Society of America. Bad bugs, no drugs: as antibiotic discovery stagnates...a public health crisis brews. Available from http://www.idsociety.org/pa/IDSA_ Paper4_final_web.pdf. Accessed January 3, 2007.
7. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657-68. (Erratum in Clin Infect Dis 2006;42:1065; comments in Clin Infect Dis 2006;43:383-4.)
8. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000;31:101-6.
9. Lautenbach E, Patel JB, Biler WB, Edelstein PH, Fishman NO. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:1162-71.
10. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwanz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006;50:1257-62.
11. Ambler RP. The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 1980;289:321-31.
12. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
13. Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004;48:1-14.
14. Babic M, Hujer AM, Bonomo RA. What's new in antibiotic resistance? Focus on β-lactamases. Drug Resist Updates 2006;9:142-56.
15. Toleman MA, Simm AM, Murphy TA, et al. Molecular characterization of SPM-I, a novel metallo-β-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J Antimicrob Chemother 2002;50:673-9.
16. Smith CA, Baker EN. Aminoglycoside antibiotic resistance by enzymatic deactivation. Curr Drug Targets Infect Disord 2002;2:143-60.
17. Miller GH, Sabatelli FJ, Hare RS, et al. The most frequent aminoglycoside resistance mechanisms-changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside resistance study groups. Clin Infect Dis 1997;24(suppl 1):S46-62.
18. Livermore DM. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992;36:2046-8.
19. Aeschlimann JR. The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other gram-negative bacteria: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2003;23:916-24.
20. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34:634-40.
21. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Med 2006;119(6 suppl 1):S3-10; discussion S62-70.
22. Deguchi T, Yasuda M, Nakano M, et al. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae. J Antimicrob Chemother 1997;40:543-9.
23. Weldhagen G, Poirel L, Nordmann P. Ambler class A extended-spectrum β-lactamase in Pseudomonas aeruginosa: novel development and clinical impact. Antimicrob Agents Chemother 2003;47:2385-92.
24. Cheng KC, Chuang YC, Wu LT, Huang GC, Yu WL. Clinical experiences of the infections caused by extended-spectrum β-lactamase-producing Serratia marcescens at a medical center in Taiwan. Jpn J Infect Dis 2006;59:147-52.
25. Manzur A, Tubau F, Pujol M, et al. Nosocomial outbreak due to extended-spectrum β-lactamase-producing Enterobacter cloacae in a cardiothoracic intensive care unit. J Clin Microbiol 2007;45:2365-9.
26. Choi SH, Lee JE, Park SJ, et al. Prevalence, microbiology, and clinical characteristics of extended-spectrum β-lactamase-producing Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii in Korea. Eur J Clin Microbiol Infect Dis 2007;26:557-61.
27. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-86.
28. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51.
29. Yague A, Cebrian L, Rodriguez-Diaz JC, et al. Expanded-spectrum β-lactamase-producing strains of E. coli: origin, characteristics and incidence in Southern Alicante (Spain) in the period 1999-2003 [in Spanish]. Enferm Infecc Microbiol Clin 2005;23:76-9.
30. DiPersio JR, Deshpande LM, Biedenbach DJ, Toleman MA, Walsh TR, Jones RN. Evolution and dissemination of extended-spectrum β-lactamase- producing Klebsiella pneumoniae: epidemiology and molecular report from the SENTRY antimicrobial surveillance program (1997-2003). Diagn Microbiol Infect Dis 2005;51:1-7.
31. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001;33:1288-94.
32. Gunseren F, Mamikoglu L, Ozturk S, et al. A surveillance study of antimicrobial resistance of gram-negative bacteria isolated from intensive care units in eight hospitals in Turkey. J Antimicrob Chemother 1999;43:373-8.
33. Sader HS, Jones RN, Gales AC, et al, for the SENTRY Latin America Study Group. Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY antimicrobial surveillance program (1997). Diagn Microbiol Infect Dis 1998;32:289-301.
34. Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the tigecycline evaluation and surveillance trial. J Infect 2007;55:49-57.
35. Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ. In vitro activity of tigecycline against 3989 gram-negative and gram-positive clinical isolates from the United States tigecycline evaluation and surveillance trial (TEST program, 2004). Diagn Microbiol Infect Dis 2005;52:173-9.
36. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial Infections. Ann Intern Med 2004;140:26-32.
37. Dandekar PK, Tetreault J, Quinn JP, Nightingale CH, Nicolau DP. Prevalence of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella isolates in a large community teaching hospital in Connecticut. Diagn Microbiol Infect Dis 2004;49:37-9.
38. Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007;57:207-15.
39. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001;45:1151-61.
40. Bradford PA, Bratu S, Urban C, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin Infect Dis 2004;39:55-60.
41. Bratu S, Mooty M, Nichani S, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 2005;49:3018-20.
42. Quale JM, Landman D, Bradford PA, et al. Molecular epidemiology of a citywide outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae infection. Clin Infect Dis 2002;35:834-41.
43. Villegas MV, Lolans K, Correa A, et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother 2006;50:2880-2.
44. Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother 2006;50:3098-101.
45. Bratu S, Brooks S, Burney S, et al. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 2007;44:972-5.
46. Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2006;43(suppl 2):S100-5.
47. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001;119(2 suppl):S397-404.
48. Govan JR, Nelson JW. Microbiology of lung infection in cystic fibrosis. Br Med Bull 1992;48:912-30.
49. Spencker FB, Haupt S, Claros MC, et al. Epidemiologic characterization of Pseudomonas aeruginosa in patients with cystic fibrosis. Clin Microbiol Infect 2000;6:600-7.
50. Crespo MP, Woodford N, Sinclair A, et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-β-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol 2004;42:5094-101.
51. Tsukayama DT, van Loon HJ, Cartwright C, et al. The evolution of Pseudomonas aeruginosa during antibiotic rotation in a medical intensive care unit: the RADAR trial. Int J Antimicrob Agents 2004;24:339-45.
52. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003;47:1681-8.
53. Navon-Venezia S, Ben-Ami R, Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005;18:306-13.
54. Karlowsky JA, Jones ME, Thornsberry C, Evangelista AT, Yee YC, Sahm DF. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin Infect Dis 2005;40(suppl 2):S89-98.
55. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004;48:4606-10.
56. Jones RN, Kirby JT, Beach ML, Biedenbach DJ, Pfaller MA. Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY antimicrobial surveillance program (1997-2000). Diagn Microbiol Infect Dis 2002;43:239-43.
57. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in U.S. intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885-8.
58. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43:1379-82.
59. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001;47:247-50.
60. Nordmann P, Poirel L. Emerging carbapenemases in gram-negative aerobes. Clin Microbiol Infect 2002;8:321-31.
61. Livermore DM, Woodford N. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006;14:413-20.
62. Toleman MA, Biedenbach D, Bennett DM, Jones RN, Walsh TR. Italian metallo-β-lactamases: a national problem? Report from the SENTRY antimicrobial surveillance programme. J Antimicrob Chemother 2005;55:61-70.
63. Toleman MA, Rolston K, Jones RN, Walsh TR. blaVIM-7, an evolutionarily distinct metallo-β-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother 2004;48:329-32.
64. Lolans K, Queenan AM, Bush K, Sahud A, Quinn JP. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-β-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother 2005;49:3538-40.
65. Hanson ND, Hossain A, Buck L, Moland ES, Thomson KS. First occurrence of a Pseudomonas aeruginosa isolate in the United States producing an IMP metallo-β-lactamase, IMP-18. Antimicrob Agents Chemother 2006;50:2272-3.
66. Aboufaycal H, Sader HS, Rolston K, et al. blaVIM-2 and blaVIM-7 carbapenemase-producing Pseudomonas aeruginosa isolates detected in a tertiary care medical center in the United States: report from the MYSTIC program. J Clin Microbiol 2007;45:614-15.
67. Yan JJ, Wu JJ, Tsai SH, Chuang CL. Comparison of the double-disk, combined disk, and Etest methods for detecting metallo-β-lactamases in gram-negative bacilli. Diag Microbiol Infect Dis 2004;49:5-11.
68. Walsh TR, Bolmstrom A, Qwarnstrom A, Gales A. Evaluation of a new Etest for detecting metallo-β-lactamases in routine clinical testing. J Clin Microbiol 2002;40:2755-9.
69. Migliavacca R, Docquier JD, Mugnaioli C, et al. Simple microdilution test for detection of metallo-β-lactamase production in Pseudomonas aeruginosa. J Clin Microbiol 2002;40:4388-90.
70. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis 2001;32(suppl 2):S104-13.
71. McGowan JE Jr. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Infect Control 2006;34(5 suppl 1):S29-37; discussion S64-73.
72. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States: national nosocomial infections surveillance system. Crit Care Med 1999;27:887-92.
73. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 2004;38:1449-59.
74. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in U.S. hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17.
75. Hujer KM, Hujer AM, Hulten EA, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother 2006;50:4114-23.
76. Hawley JS, Murray CK, Griffith ME, et al. Susceptibility of Acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob Agents Chemother 2007;51:376-8.
77. Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis 2003;37:214-20.
78. Landman D, Quale JM, Mayorga D, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med 2002;162:1515-20.
79. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006;43(suppl 2):S49-56.
80. Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. J Clin Microbiol 2000;38:3299-305.
81. Corvee S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud A. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J Antimicrob Chemother 2003;52:629-35.
82. Hujer KM, Hamza NS, Hujer AM, et al. Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 β-lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother 2005;49:2941-8.
83. Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003;47:3442-7.
84. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353-8.
85. Kiffer CR, Kuti JL, Eagye KJ, Mendes C, Nicolau DP. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil. Int J Antimicrob Agents 2006;28:340-4.
86. Moczygemba LR, Frei CR, Burgess DS. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum β-lactamases. Clin Ther 2004;26:1800-7.
87. Livermore DM, Carter MW, Bagel S, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001;45:1860-7.
88. Livermore DM, Oakton KJ, Carter MW, Warner M. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent β-lactamases. Antimicrob Agents Chemother 2001;45:2831-7.
89. Turner PJ. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC program. Diagn Microbiol Infect Dis 2006;56:341-4.
90. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004;48:3086-92.
91. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI document M100-S16: 16th informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
92. Souli M, Kontopidou FV, Koratzanis E, et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006;50:3166-9.
93. Duenas Diez AI, Bratos Perez MA, Eiros Bouza JM, et al. Susceptibility of the Acinetobacter calcoaceticus-A. baumannii complex to imipenem, meropenem, sulbactam and colistin. Int J Antimicrob Agents 2004;23:487-93.
94. Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006;43(suppl 2):S89-94.
95. Motaouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006;53: 274-8.
96. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007;11:402-6.
97. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin [online exclusive article]. BMC Infect Dis 2005;5:1. Available from http://www.biomedcentral.com/1471-2334/5/1.
98. Reina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005;31(8): 1058-65.
99. Kallel H, Bahloul M, Hergafi L, et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 2006;28:366-9.
100. Hachem RY, Chemaly RF, Ahmar CA, et al. Colistin is effective in the treatment of multidrug-resistant Pseudomonas aeruginosa infections in cancer patients. Antimicrob Agents Chemother 2007;51:1905-11.
101. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) gram-negative bacteria [online exclusive article]. BMC Infect Dis 2005;5:24. Available from http://www.biomedcentral.com/1471-2334/5/24.
102. Falagas ME, Bliziotis IA. Pandrug-resistant gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 2007;29:630-6.
103. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001;45:781-5.
104. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents 2005;25: 11-25.
105. Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;49:3624-30.
106. Falagas ME, Kasiakou SK. Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world. Antimicrob Agents Chemother 2006;50:2274-5.
107. Li J, Nation RL, Turnidge JD. Defining the dosage units for colistin methanesulfonate: urgent need for international harmonization [letter and author reply]. Antimicrob Agents Chemother 2006;50:4231-2.
108. Lee SY, Kuti JL, Nicolau DP. Polymyxins: older antibiotics for a new threat. Conn Med 2006;70:25-8.
109. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies [online exclusive article]. Crit Care 2006;10:R27. Available from http://ccforum.eom/content/10/1/R27.
110. Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005;56:128-32.
111. Parchuri S, Mohan S, Cunha BA. Extended-spectrum β-lactamase-producing Klebsiella pneumoniae chronic ambulatory peritoneal dialysis peritonitis treated successfully with polymyxin B. Heart Lung 2005;34:360-3.
112. Segal-Maurer S, Mariano N, Qavi A, Urban C, Rahal JJ Jr. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Clin Infect Dis 1999;28:1134-8.
113. Karabinis A, Paramythiotou E, Mylona-Petropoulou D, et al. Colistin for Klebsiella pneumoniae-associated sepsis [online exclusive article]. Clin Infect Dis 2004;38:e7-9. Available from http://www.journals. uchicago.edu/doi/pdf/10.1086/ 380461.
114. Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 2005;25:185-92.
115. Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005;56:611-14.
116. Morosini MI, Garcia-Castillo M, Coque TM, et al. Antibiotic coresistance in extended-spectrum β-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006;50:2695-9.
117. Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones RN. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn Microbiol Infect Dis 2005;52:209-13.
118. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005;52:181-6.
119. Daly MW, Riddle DJ, Ledeboer NA, Dunne WM, Ritchie DJ. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 2007;27:1052-7.
120. Taccone FS, Rodriguez-Villalobos H, De Backer D, et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 2006;25:257-60.
121. Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007;27:980-7.
122. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007;27:1198-201.
123. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-31.
124. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007;59:772-4.
125. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-31.
126. Vila J, Marcos A, Marco F, et al. In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1993;37:138-41.
127. Tong W, Wang R, Chai D, Li Z, Pei F. In vitro activity of cefepime combined with sulbactam against clinical isolates of carbapenem-resistant Acinetobacter spp. Int J Antimicrob Agents 2006;28:454-6.
128. Kiffer CR, Sampaio JL, Sinto S, et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis 2005;52:317-22.
129. Swenson JM, Killgore GE, Tenover FC. Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods. J Clin Microbiol 2004;42:5102-8.
130. Corbella X, Ariza J, Ardanuy C, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998;42:793-802.
131. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002;34:1425-30.
132. Koulenti D, Rello J. Gram-negative bacterial pneumonia: aetiology and management. Curr Opin Pulm Med 2006;12:198-204.
133. Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis 2007;39:38-43.
134. DeRyke CA, Kuti JL, Nicolau DP. Questioning the paradigm: monotherapy vs combination antimicrobial therapy for treatment of Pseudomonas aeruginosa. Conn Med 2005;69:271-5.
135. Saiman L, Mehar F, Niu WW, et al. Antibiotic susceptibility of multiple resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996;23:532-7.
136. Zhou J, Chen Y, Tabibi S, Alba L, Garber E, Saiman L. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2007;51: 1085-8.
137. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006;26:1320-32.
138. Gillespie EL, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials: treatment optimisation. Expert Opin Drug Metab Toxicol 2005;1:351-61.
139. Kuti JL, Moss KM, Nicolau DP, Knauft RF. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy 2004;24:1641-5.
140. Capitano B, Nicolau DP, Potoski BA, et al. Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. Pharmacotherapy 2004;24:803-7.
141. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-63.
142. Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals. Int J Antimicrob Agents 2006;28:433-8.